Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

INT-007 is bioequivalent to branded tablet for erectile dysfunction

Sep. 6, 2010

New MCH1 receptor antagonists claimed by sanofi-aventis

Sep. 6, 2010

Orexigen and Takeda to co-commercialize Contrave in North America

Sep. 3, 2010

LG Life Sciences discloses new xanthine oxidase inhibitors

Sep. 3, 2010

NIH grants funding to Bionovo for obesity and metabolic syndrome study

Sep. 3, 2010

Halozyme begins phase II trials of PH-20 in type 1 and type 2 diabetes

Sep. 3, 2010

FDA approves Omnitrope for idiopathic short stature

Sep. 3, 2010

New GHRH receptor antagonists disclosed by sanofi-aventis

Sep. 3, 2010

Alipogene tiparvovec shows safety and efficacy in subjects with LPL deficiency / News in Context

Sep. 3, 2010

Biodel changes name of insulin formulation from VIAject to Linjeta

Sep. 2, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 24, 2026.
To viral or not to viral: In vivo CAR T debates delivery tech
BioWorld
The field of cell and gene therapy is moving toward a new phase of scalability and clinical durability, with in vivo chimeric antigen receptor (CAR) T-cell...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 21, 2026
KBN-2201 reverses key features of Alzheimer’s in mice
BioWorld Science
Researchers from Ajou University School of Medicine reported the preclinical efficacy of KBN-2201 in a mouse model of late-stage Alzheimer’s disease.
To viral or not to viral: In vivo CAR T debates delivery tech
BioWorld Science
The field of cell and gene therapy is moving toward a new phase of scalability and clinical durability, with in vivo chimeric antigen receptor (CAR) T-cell...